^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Oncopore (ruxotemitide)

i
Other names: LTX-315, lactoferrin pharmacophore LTX-315, LTX 315, VP-315
Associations
Company:
Lytix, Verrica
Drug class:
Immunostimulant, Cell death stimulant, Cell membrane modulator
Related drugs:
Associations
28d
NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma (clinicaltrials.gov)
P2, N=27, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
Enrollment open
|
Keytruda (pembrolizumab) • Oncopore (ruxotemitide)
1m
New P2 trial • Combination therapy
|
Keytruda (pembrolizumab) • Oncopore (ruxotemitide)
1m
VP-315-201: Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma (clinicaltrials.gov)
P2, N=92, Completed, Verrica Pharmaceuticals Inc. | Recruiting --> Completed
Trial completion
|
Oncopore (ruxotemitide)
7ms
A Transformable Specific-Responsive Peptide for One-Step Synergistic Therapy of Bladder Cancer. (PubMed, Small)
The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR-1; ii) Transformable unit could self-assembly and trigger nanofibers formation; iii) Reactive unit could specifically cleaved by MMP-2/9 in tumor micro-environment; iv) Immune unit, stimulate the release of immune cells when LTX-315 (Immune-associated oncolytic peptide) exposed...All above processes together contribute to the increasing survival rate of tumor-bearing mice by nearly 4-folds. This work presented a unique design for the biological application of one-step synergistic therapy of bladder cancer.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • CD8 (cluster of differentiation 8) • MMP2 (Matrix metallopeptidase 2) • CALR (Calreticulin) • MMP9 (Matrix metallopeptidase 9)
|
Oncopore (ruxotemitide)
8ms
LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells. (PubMed, Front Immunol)
Critically, the effects of LTX-315 on DCs the consequent promotion of anti-melanoma immunity depend on the cytosolic signal transducer myeloid differentiation response gene 88 (MyD88). These results cast light on the mechanisms by which LTX-315 induces DC maturation and hence elicits anticancer immunity, with important implications for the use of LTX-315 as an anticancer immunotherapeutic.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TLR7 (Toll Like Receptor 7)
|
Oncopore (ruxotemitide)
1year
ATLAS-IT-05: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma (clinicaltrials.gov)
P2, N=20, Active, not recruiting, Lytix Biopharma AS | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • Oncopore (ruxotemitide)
almost2years
Enhanced efficacy of direct immunochemotherapy for hepatic cancer with image-guided intratumoral radiofrequency hyperthermia. (PubMed, J Immunother Cancer)
Intratumoral RFA-associated RFH could enhance the efficacy of immunochemotherapy of LTX-315 with liposomal doxorubicin for HCC, which may provide a new strategy to increase the curative efficacy of thermal ablation for medium-to-large HCC.
Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL18 (Interleukin 18) • IL4 (Interleukin 4)
|
Oncopore (ruxotemitide)
2years
ATLAS-IT-05: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma (clinicaltrials.gov)
P2, N=20, Recruiting, Lytix Biopharma AS | Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • Oncopore (ruxotemitide)
over2years
How Strong and Sustained Activation of the Estrogen Receptor-mediated Anticipatory Unfolded Protein Response Kills Breast and Ovarian Cancer Cells (ENDO 2022)
Suggesting a broad role of TRPM4 in the actions of necrosis inducing anticancer drugs, TRPM4 knockout also inhibited necrosis induced by unrelated anticancer therapies, the mitochondrial targeting oncolytic peptide, LTX-315 and the Ca2+ channel targeting agent, Englerin A. Since increasing expression TRPM4 by viral transduction results in progressively increased sensitivity of ER positive breast cancer cells to killing by ErSO, this enables identification of breast cancer patients whose elevated TRPM4 levels make them most likely to benefit from this novel therapy. The TRPM4 pathway is a new mechanism for sustained lethal activation of the UPR and for targeting ER positive breast and ovarian cancer.
IO biomarker
|
ER (Estrogen receptor)
|
ER positive • ER Y537S
|
Oncopore (ruxotemitide)
over2years
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. (PubMed, J Immunother Cancer)
LTX-315 was first identified as a peptide drug inducing PD-L1 downregulation via ATP11B. Therefore, LTX-315, or the development of ATP11B-targeting drugs, might improve the efficacy of cancer immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
ATP1B1 (ATPase Na+/K+ transporting subunit beta 1) • CMTM6 (CKLF Like MARVEL Transmembrane Domain Containing 6)
|
PD-L1 expression
|
Oncopore (ruxotemitide)
3years
Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway. (PubMed, J Biochem Mol Toxicol)
LTX-315 can inhibit the resistance of OC cells to DDP in vitro and plays a role by regulating Beclin-1/phosphatidylinositol-3-kinase/mTOR signaling pathway.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • BECN1 (Beclin 1)
|
BCL2 expression • BAX expression
|
cisplatin • Oncopore (ruxotemitide)
3years
Smart co-delivery of miR-34a and cytotoxic peptides (LTX-315 and melittin) by chitosan based polyelectrolyte nanocarriers for specific cancer cell death induction. (PubMed, Mater Sci Eng C Mater Biol Appl)
The spherical nanocarriers with an average size of 123 ± 5 nm and a zeta potential of -36 ± 1 mV demonstrated controlled-release of gene and peptides ensured a synergistic effect in establishing multiple cell death pathways on chemoresistance human breast adenocarcinoma cell line, MDA-MB-231. In vitro cell viability assays also revealed no cytotoxicity for the nanocarriers, and an IC50 of 15 μg/mL and 150 μg/mL for melittin and LTX-315, respectively, after 48 h, whereas co-delivery of melittin with miR-34a increased smart death induction by 54%.
Journal
|
MIR34A (MicroRNA 34a-5p)
|
Oncopore (ruxotemitide)
over3years
Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma. (PubMed, J Control Release)
The immunotherapeutic effect was evidenced by secretion of IL-6, IFN-γ and TNF-α, tumor infiltration of CD8+ CTLs and T, and induction of T and T in spleen. This study opens a new avenue to oncolytic peptides, which enables durable immunotherapy of tumors via systemic administration.
Clinical • Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
Oncopore (ruxotemitide)
over3years
LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04) (clinicaltrials.gov)
P2, N=6, Active, not recruiting, Lytix Biopharma AS | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
CD8 (cluster of differentiation 8)
|
Oncopore (ruxotemitide)
over3years
Clinical • Enrollment open • Combination therapy
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
|
PD-L1 expression • MSI-H/dMMR • BRAF mutation • BRCA mutation
|
Keytruda (pembrolizumab) • Oncopore (ruxotemitide)
over3years
Clinical • New P2 trial • Combination therapy
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
|
PD-L1 expression • MSI-H/dMMR • BRAF mutation • BRCA mutation
|
Keytruda (pembrolizumab) • Oncopore (ruxotemitide)